Analyst: New UK monkeypox strategy might boost Bavarian Nordic orders

The UK plans to offer Bavarian Nordic’s vaccine, Imvanex, to a broader segment of people at risk of exposure. Wider use could lead to more orders from governments, assesses one analyst.

Photo: Dado Ruvic/Reuters/Ritzau Scanpix

On Tuesday, the UK announced plans to provide Bavarian Nordic’s vaccine, Imvanex, to a wider segment of people at-risk of exposure, including gay and bisexual men. Previously, vaccination was only recommended for those who had been in close contact with someone carrying the infection.

Reacting to the news, Sydbank analyst Søren Løntoft Hansen assesses that this could lead to even more vaccine orders for the Danish biotech firm, which announced at the beginning of June that it had a stockpile of bulk vaccines equating to ”millions of doses” ready for conversion.

Already a subscriber? Log in.

Read the whole article

Get access for 14 days for free.
No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.

  • Access all locked articles
  • Receive our daily newsletters
  • Access our app
An error has occured. Please try again later.

Get full access for you and your coworkers.

Start a free company trial today

More from MedWatch

Further reading

Related articles

Latest news

See all jobs